Comparing Cardiovascular Outcomes With Degarelix or Leuprolide as Prostate Cancer Therapy-Applying Real-world Data to Clinical Trial Emulation.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2021.31429
Abstract: Since the early 1980s, androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonist or antagonist therapies has remained the primary systemic therapy for men with prostate cancer, owing to the fundamental reliance of the disease… read more here.
Keywords: real world; trial; comparing cardiovascular; prostate cancer ... See more keywords
Real-world Associations of US Cystic Fibrosis Newborn Screening Programs With Nutritional and Pulmonary Outcomes.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA pediatrics"
DOI: 10.1001/jamapediatrics.2022.2674
Abstract: Importance Newborn screening (NBS) for cystic fibrosis (CF) has been universal in the US since 2010, but its association with clinical outcomes is unclear. Objective To describe the real-world effectiveness of NBS programs for CF… read more here.
Keywords: age; cohort; age years; newborn screening ... See more keywords
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26475
Abstract: Steroid‐refractory (SR) acute graft‐versus‐host disease (aGVHD) is one of the leading causes of early mortality after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We investigated the efficacy, safety, prognostic factors, and optimal therapeutic protocol for SR‐aGVHD… read more here.
Keywords: basiliximab; steroid refractory; refractory acute; acute graft ... See more keywords
Real‐world Big‐data: Strengths and weaknesses of ASCO's CancerLinQ® discovery multiple myeloma dataset
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26921
Abstract: Real-world data (RWD) are increasingly relevant in oncology practice. RWD can shed light on outcomes of patients who are underrepresented or ineligible for clinical trials or with rare cancers that are difficult to study prospectively.… read more here.
Keywords: oncology; cancerlinq discovery; rwd; multiple myeloma ... See more keywords
Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Neurology"
DOI: 10.1002/ana.25737
Abstract: To assess real‐world effectiveness of initial treatment with newer compared to injectable disease‐modifying therapies (DMTs) on disease activity in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS). read more here.
Keywords: real world; effectiveness initial; world effectiveness; modifying therapies ... See more keywords
Real-World Outcomes of Endovascular Thrombectomy for Basilar Artery Occlusion: Results of the BArONIS Study.
Sign Up to like & getrecommendations! Published in 2023 at "Annals of neurology"
DOI: 10.1002/ana.26640
Abstract: OBJECTIVE To evaluate clinical outcomes of endovascular thrombectomy (EVT) for acute basilar artery occlusion (BAO) using population-level data from the United States. METHODS Weighted discharge data from the National Inpatient Sample were queried to identify… read more here.
Keywords: outcomes endovascular; endovascular thrombectomy; basilar artery; artery occlusion ... See more keywords
Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies
Sign Up to like & getrecommendations! Published in 2022 at "Brain and Behavior"
DOI: 10.1002/brb3.2662
Abstract: Current German and European guidelines suggest migraine patients undertake a treatment break after 9 to 12 months of treatment with CGRP (pathway) monoclonal antibodies. read more here.
Keywords: pathway monoclonal; world evidence; treatment break; treatment ... See more keywords
A retrospective observational study of intraductal breast papilloma and its coexisting lesions: A real‐world experience
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3308
Abstract: Breast intraductal papilloma is a heterogeneous group. The aim of the study is to investigate the intraductal breast papilloma and its coexisting lesions retrospectively in real‐world practice. read more here.
Keywords: papilloma coexisting; real world; coexisting lesions; breast ... See more keywords
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3470
Abstract: Limited information is available on the efficacy of front‐line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real‐world patients and performed… read more here.
Keywords: real world; ibrutinib; lymphocytic leukemia; bendamustine rituximab ... See more keywords
Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5061
Abstract: Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real‐world data on this regimen are limited in this setting. read more here.
Keywords: dosing patterns; melanoma; nivolumab dosing; world nivolumab ... See more keywords
Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5062
Abstract: Poly ADP‐ribose polymerase inhibitors (PARPis) have significantly improved clinical effects in gynecological oncology. However, PARPis could also induce severe organ system toxicities, including the hematological system. Our study aimed to extensively characterize the hematological toxicities… read more here.
Keywords: hematological toxicities; system; toxicities parp; real world ... See more keywords